It may be possible to use a drug to prevent some of the lasting and
crippling damage caused by a stroke, according to doctors in the US and Canada.
A safety trial, published in the Lancet Neurology medical journal,
suggested the chemical NA-1 was safe to use. The study on 185 people also
hinted that patients given the drug developed fewer regions of damaged brain
tissue.
The Stroke Association said that it was promising, but needed more
research. Tests in primates had suggested NA-1 prevented brain cells dying when
a stroke starved them of oxygen. A small trial was set up at 14 hospitals in
the US and Canada. Patients who took part were having an operation to repair a
brain aneurysm, a weakened blood vessel, which could rupture, are at increased
risk of a stroke. Ninety-two people had the drug injected into a vein, while
another 93 were injected with salty water.
'Safe'
The doctors concluded that NA-1 was safe, with only two patients having
mild side effects. However, brain scans also showed that fewer brain lesions,
damaged areas of tissue, formed in patients given the drug. The doctors
involved said the study provided evidence that "neuroprotection is
achievable" but said that "a larger trial is necessary to investigate
the robustness of the effect".
Prof Markku Kaste, from Helsinki University Central Hospital, said:
"Age is the greatest risk factor for stroke. Because of the global
population ageing, the number and burden of strokes will increase." He
said previous trials to use drugs to protect the brain had resulted in failure.
His said this drug still need to be assessed in much larger clinical trials
before its effectiveness was known.
Dr Peter Coleman, from the Stroke Association charity said: "We
welcome any treatment that could protect brain cells after a stroke and limit
the amount of brain damage. This potential treatment appears promising, but a
lot more research is needed." The trial was funded by the
biopharmaceutical companies NoNO and Arbor Vita.
BBC News
Please share
BBC News
Please share
No comments:
Post a Comment